Farxiga in Elderly Patients
Farxiga (dapagliflozin) 10 mg once daily is safe and effective in elderly patients aged 65 years and older, with no dose adjustment required based on age alone. 1
Dosing Recommendations
Standard Dosing for Elderly
- 10 mg once daily for heart failure, chronic kidney disease, and cardiovascular risk reduction indications 1
- 5-10 mg once daily for glycemic control in type 2 diabetes 1
- No age-based dose adjustment needed - efficacy and safety are consistent across all age groups 1
Renal Function-Based Adjustments (Critical in Elderly)
For non-glycemic indications (heart failure, CKD):
- eGFR ≥25 mL/min/1.73 m²: Use standard 10 mg dose 2
- eGFR <25 mL/min/1.73 m²: Do not initiate, but may continue if already established 2
- Once started, continue even if eGFR falls below 25 mL/min/1.73 m² 1
For glycemic control:
- eGFR ≥45 mL/min/1.73 m²: Standard dosing 1
- eGFR <45 mL/min/1.73 m²: Not recommended for glucose lowering (ineffective due to mechanism of action) 1
Clinical Evidence in Elderly
The DECLARE-TIMI 58 trial specifically analyzed 7,907 patients ≥65 years (including 1,096 patients ≥75 years) and demonstrated:
- Consistent cardiovascular benefits across all age groups (HR 0.77 for ages 65-75 years for CV death/HF hospitalization) 3
- No heterogeneity in treatment effect by age (interaction P=0.53) 3
- Reduced major hypoglycemia in elderly (HR 0.50 in ages 65-75 years) 3
In DAPA-CKD, DAPA-HF, and DELIVER trials, 42-76% of participants were >65 years, with similar safety and efficacy profiles 1
Key Monitoring Requirements
Volume Status Assessment
Critical in elderly due to higher hypotension risk:
- Assess volume status before initiation 1
- Correct volume depletion prior to starting 1
- Monitor blood pressure regularly - elderly patients ≥65 years had higher rates of hypotension 1
- Consider proactive diuretic dose reduction in high-risk patients 2
Renal Function Monitoring
- Check eGFR before initiation 1
- Expect transient eGFR decline of up to 15% within first 1-3 months (generally resolves) 4
- Monitor more frequently as eGFR declines below 60 mL/min/1.73 m² 2
- Do not discontinue for transient eGFR decline unless patient is intolerant 2
Metabolic Monitoring
- Monitor for hypoglycemia if on insulin or sulfonylureas - adjust these agents proactively 2
- Check for ketones during acute illness (blood or urine) 2
- Vitamin B12 if on concurrent metformin >4 years 2
Contraindications
Absolute:
- History of serious hypersensitivity to dapagliflozin 1
- Type 1 diabetes (markedly increased ketoacidosis risk) 4, 1
- Dialysis 1
Relative (use with extreme caution):
- Severe hepatic impairment (assess benefit-risk individually) 1
- History of recurrent genital mycotic infections 4
Common Adverse Effects and Management
Genital Mycotic Infections (Most Common)
- Incidence: 10-15% in women, lower in men 4, 2
- Management: Counsel on genital hygiene; most respond to topical antifungals without drug discontinuation 4
- Serious cases: Fournier's gangrene reported rarely 2
Volume Depletion/Hypotension
- Higher risk in elderly ≥65 years 1
- Mitigation: Assess volume status pre-treatment, reduce diuretics if appropriate 2
- Sick day protocol: Hold during acute illness with reduced oral intake 4, 2
Diabetic Ketoacidosis (Rare but Serious)
- Risk factors: Insulin reduction, acute illness, surgery, reduced caloric intake 1
- Prevention: Maintain at least low-dose insulin in insulin-requiring patients; withhold 3 days before major surgery 1
- Recognition: Educate on symptoms; may be euglycemic 2
Acute Kidney Injury
- Actually reduced with dapagliflozin in trials 4
- Monitor during: Volume depletion, concurrent nephrotoxic drugs 4
Other Considerations
- Urinary tract infections: No increased risk versus placebo 3
- Fractures: Balanced with placebo in elderly populations 3
- Amputations: No increased risk 3
Special Considerations for Elderly
Cardiovascular Disease
Strong recommendation for use in elderly with:
- Heart failure (any ejection fraction) 4
- Type 2 diabetes with established CVD or multiple risk factors 4
- Chronic kidney disease with albuminuria 4, 5
Chronic Kidney Disease
- Initiate down to eGFR 25 mL/min/1.73 m² for cardiorenal protection 2
- Continue even if eGFR declines below initiation threshold 2
- Benefits include 44% reduction in composite kidney outcomes 4
Polypharmacy Management
- Reduce insulin/sulfonylurea doses to prevent hypoglycemia 2
- No significant drug interactions with common cardiovascular medications 6
- Compatible with ACE inhibitors/ARBs - use together for additive benefit 4, 5
Practical Implementation Algorithm
- Assess eligibility: Check for contraindications (type 1 diabetes, dialysis, hypersensitivity)
- Measure baseline eGFR: Proceed if ≥25 mL/min/1.73 m² (or ≥45 for glycemic control only)
- Evaluate volume status: Correct depletion before starting
- Adjust background therapy: Reduce insulin/sulfonylureas if hypoglycemia risk
- Start 10 mg once daily (or 5 mg for glycemic control, titrate to 10 mg if needed)
- Monitor at 1 month: Check eGFR (expect transient decline), blood pressure, symptoms
- Continue long-term: Do not stop for eGFR decline unless <25 mL/min/1.73 m² at initiation or dialysis started
- Sick day protocol: Hold during acute illness with reduced intake; resume when stable
The evidence strongly supports dapagliflozin use in elderly patients across multiple indications, with consistent benefits in reducing cardiovascular death, heart failure hospitalization, and kidney disease progression, regardless of age 4, 2, 3.